Search

Your search keyword '"McCarthy, Philip L."' showing total 1,204 results
Start Over Author "McCarthy, Philip L."

Refine your results

more »

more »

more »

more »

more »
1,204 results on '"McCarthy, Philip L."'

3. Galectin-3 predicts acute GvHD and overall mortality post reduced intensity allo-HCT: a BMT-CTN biorepository study

Author

McCarthy, Philip L., Attwood, Kristopher M., Liu, Xiaojun, Chen, George L., Minderman, Hans, Alousi, Amin, Bashey, Asad, Lowsky, Robert, Miklos, David B., Hansen, John, Westervelt, Peter, Yanik, Gregory, Waller, Edmund K., Howard, Alan, Blazar, Bruce R., Wallace, Paul K., Reshef, Ran, Horowitz, Mary M., Maziarz, Richard T., Levine, John E., and Mohammadpour, Hemn

Published
2024
Full Text
View/download PDF

4. The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma

Author

Holstein, Sarah A, Bahlis, Nizar, Bergsagel, P Leif, Bhutani, Manisha, Bolli, Niccolo, Brownstein, Carrie, Demolis, Pierre, Foureau, David, Gay, Francesca, Ghobrial, Irene M, Gormley, Nicole, Hillengass, Jens, Kaiser, Martin, Maus, Marcela V, Melenhorst, J Joseph, Merz, Maximilian, Dwyer, Michael O, Paiva, Bruno, Pasquini, Marcelo C, Shah, Nina, Wong, Sandy W, Usmani, Saad Z, and McCarthy, Philip L

Subjects
Transplantation, Rare Diseases, Cancer, Hematology, Good Health and Well Being, Humans, Bone Marrow, Diterpenes, High-Throughput Nucleotide Sequencing, Multiple Myeloma, Neoplasm, Residual, Minimal residual disease, Immune profiling, Multiple myeloma, Endpoint, CAR T-cell, Cellular therapy
Abstract

The fifth annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma was conducted as one of the American Society of Hematology Annual Meeting Scientific Workshops on Thursday December 3, 2020. This workshop focused on four main topics: (1) integrating minimal residual disease into clinical trial design and practice; (2) the molecular and immunobiology of disease evolution and progression in myeloma; (3) adaptation of next-generation sequencing, next-generation flow cytometry, and cytometry by time of flight techniques; and (4) chimeric antigen receptor T-cell and other cellular therapies for myeloma. In this report, we provide a summary of the workshop presentations and discuss future directions in the field.

Published
2021

5. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events

Author

Maus, Marcela V, Alexander, Sara, Bishop, Michael R, Brudno, Jennifer N, Callahan, Colleen, Davila, Marco L, Diamonte, Claudia, Dietrich, Jorg, Fitzgerald, Julie C, Frigault, Matthew J, Fry, Terry J, Holter-Chakrabarty, Jennifer L, Komanduri, Krishna V, Lee, Daniel W, Locke, Frederick L, Maude, Shannon L, McCarthy, Philip L, Mead, Elena, Neelapu, Sattva S, Neilan, Tomas G, Santomasso, Bianca D, Shpall, Elizabeth J, Teachey, David T, Turtle, Cameron J, Whitehead, Tom, and Grupp, Stephan A

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Pediatric, Immunization, Cancer, Biotechnology, Clinical Research, Patient Safety, Vaccine Related, 5.1 Pharmaceuticals, Development of treatments and therapeutic interventions, Drug-Related Side Effects and Adverse Reactions, Guidelines as Topic, Humans, Immunologic Factors, Immunotherapy, Retrospective Studies, adoptive, cell engineering, chimeric antigen, guidelines as topic, hematological neoplasms, immunotherapy, receptors, Oncology and carcinogenesis
Abstract

Immune effector cell (IEC) therapies offer durable and sustained remissions in significant numbers of patients with hematological cancers. While these unique immunotherapies have improved outcomes for pediatric and adult patients in a number of disease states, as 'living drugs,' their toxicity profiles, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), differ markedly from conventional cancer therapeutics. At the time of article preparation, the US Food and Drug Administration (FDA) has approved tisagenlecleucel, axicabtagene ciloleucel, and brexucabtagene autoleucel, all of which are IEC therapies based on genetically modified T cells engineered to express chimeric antigen receptors (CARs), and additional products are expected to reach marketing authorization soon and to enter clinical development in due course. As IEC therapies, especially CAR T cell therapies, enter more widespread clinical use, there is a need for clear, cohesive recommendations on toxicity management, motivating the Society for Immunotherapy of Cancer (SITC) to convene an expert panel to develop a clinical practice guideline. The panel discussed the recognition and management of common toxicities in the context of IEC treatment, including baseline laboratory parameters for monitoring, timing to onset, and pharmacological interventions, ultimately forming evidence- and consensus-based recommendations to assist medical professionals in decision-making and to improve outcomes for patients.

Published
2020

6. Shared graft-versus-leukemia minor histocompatibility antigens in DISCOVeRY-BMT

Author

Olsen, Kelly S., Jadi, Othmane, Dexheimer, Sarah, Bortone, Dante S., Vensko, Steven P., II, Bennett, Sarah, Tang, Hancong, Diiorio, Marisa, Saran, Tanvi, Dingfelder, David, Zhu, Qianqian, Wang, Yiwen, Haiman, Christopher A., Pooler, Loreall, Sheng, Xin, Webb, Amy, Pasquini, Marcelo C., McCarthy, Philip L., Spellman, Stephen R., Weimer, Eric, Hahn, Theresa, Sucheston-Campbell, Lara, Armistead, Paul M., and Vincent, Benjamin G.

Published
2023
Full Text
View/download PDF

8. Spatiotemporal assessment of immunogenomic heterogeneity in multiple myeloma

Author

Merz, Maximilian, Hu, Qiang, Merz, Almuth Maria Anni, Wang, Jie, Hutson, Nicholas, Rondeau, Cherie, Celotto, Kimberly, Belal, Ahmed, Alberico, Ronald, Block, AnneMarie W., Mohammadpour, Hemn, Wallace, Paul K., Tario, Joseph, Luce, Jesse, Glenn, Sean T., Singh, Prashant, Samur, Mehmet, Munshi, Nikhil, Liu, Song, McCarthy, Philip L., Wei, Lei, and Hillengass, Jens

Published
2023
Full Text
View/download PDF

10. Proceedings from the Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Immune and Cellular Therapy in Multiple Myeloma

Author

Holstein, Sarah A., Asimakopoulos, Fotis, Azab, Abdel Kareem, Bianchi, Giada, Bhutani, Manisha, Crews, Leslie A., Cupedo, Tom, Giles, Hannah, Gooding, Sarah, Hillengass, Jens, John, Lukas, Kaiser, Shari, Lee, Lydia, Maclachlan, Kylee, Pasquini, Marcelo C., Pichiorri, Flavia, Shah, Nina, Shokeen, Monica, Shy, Brian R., Smith, Eric L., Verona, Raluca, Usmani, Saad Z., and McCarthy, Philip L.

Published
2022
Full Text
View/download PDF

11. Deciphering spatial genomic heterogeneity at a single cell resolution in multiple myeloma

Author

Merz, Maximilian, Merz, Almuth Maria Anni, Wang, Jie, Wei, Lei, Hu, Qiang, Hutson, Nicholas, Rondeau, Cherie, Celotto, Kimberly, Belal, Ahmed, Alberico, Ronald, Block, AnneMarie W., Mohammadpour, Hemn, Wallace, Paul K., Tario, Joseph, Luce, Jesse, Glenn, Sean T., Singh, Prashant, Herr, Megan M., Hahn, Theresa, Samur, Mehmet, Munshi, Nikhil, Liu, Song, McCarthy, Philip L., and Hillengass, Jens

Published
2022
Full Text
View/download PDF

12. Outcomes in Patients (pts) with R/R Large B-Cell Lymphoma (LBCL) Who Received Nonconforming Product (NCP) to Commercial Release of Lisocabtagene Maraleucel (liso-cel) in the United States (US)

Author

Caimi, Paolo, primary, Schuster, Stephen J., additional, Nastoupil, Loretta J., additional, Grover, Natalie, additional, Hoda, Daanish, additional, Karmali, Reem, additional, Hu, Bei, additional, Locke, Frederick L., additional, McCarthy, Philip L., additional, Palomba, M. Lia, additional, Suh, Hyung C., additional, Pasquini, Marcelo C., additional, Balint, Catherine, additional, Bernasconi, David, additional, Jude, Veronica, additional, Gharibo, Mecide, additional, and Jacobson, Caron, additional

Published
2024
Full Text
View/download PDF

13. Novel genetic variants associated with mortality after unrelated donor allogeneic hematopoietic cell transplantation

Author

Hahn, Theresa, Wang, Junke, Preus, Leah M., Karaesmen, Ezgi, Rizvi, Abbas, Clay-Gilmour, Alyssa I., Zhu, Qianqian, Wang, Yiwen, Yan, Li, Liu, Song, Stram, Daniel O., Pooler, Loreall, Sheng, Xin, Haiman, Christopher A., Berg, David Van Den, Webb, Amy, Brock, Guy, Spellman, Stephen R., Onel, Kenan, McCarthy, Philip L., Pasquini, Marcelo C., and Sucheston-Campbell, Lara E.

Published
2021
Full Text
View/download PDF

14. Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee

Author

Kumar, Shaji, Baizer, Lawrence, Callander, Natalie S., Giralt, Sergio A., Hillengass, Jens, Freidlin, Boris, Hoering, Antje, Richardson, Paul G., Schwartz, Elena I., Reiman, Anthony, Lentzsch, Suzanne, McCarthy, Philip L., Jagannath, Sundar, Yee, Andrew J., Little, Richard F., and Raje, Noopur S.

Published
2022
Full Text
View/download PDF

15. Pre-HCT mosaicism increases relapse risk and lowers survival in acute lymphoblastic leukemia patients post–unrelated HCT

Author

Wang, Yiwen, Zhou, Weiyin, Wang, Junke, Karaesmen, Ezgi, Tang, Hancong, McCarthy, Philip L., Pasquini, Marcelo C., Wang, Youjin, McReynolds, Lisa J., Katki, Hormuzd A., Machiela, Mitchell J., Yeager, Meredith, Pooler, Loreall, Sheng, Xin, Haiman, Christopher A., Van Den Berg, David, Spellman, Stephen R., Wang, Tao, Kuxhausen, Michelle, Chanock, Stephen J., Lee, Stephanie J., Clay-Gilmour, Alyssa I., Hahn, Theresa E., Gadalla, Shahinaz M., and Sucheston-Campbell, Lara E.

Published
2021
Full Text
View/download PDF

17. Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling

Author

Holstein, Sarah A., Howard, Alan, Avigan, David, Bhutani, Manisha, Cohen, Adam D., Costa, Luciano J., Dhodapkar, Madhav V., Gay, Francesca, Gormley, Nicole, Green, Damian J., Hillengass, Jens, Korde, Neha, Li, Zihai, Mailankody, Sham, Neri, Paola, Parekh, Samir, Pasquini, Marcelo C., Puig, Noemi, Roodman, G. David, Samur, Mehmet Kemal, Shah, Nina, Shah, Urvi A., Shi, Qian, Spencer, Andrew, Suman, Vera J., Usmani, Saad Z., and McCarthy, Philip L.

Published
2020
Full Text
View/download PDF

20. Galectin-3 predicts acute GvHD and overall mortality post reduced intensity allo-HCT: a BMT-CTN biorepository study

Author

McCarthy, Philip L., primary, Attwood, Kristopher M., additional, Liu, Xiaojun, additional, Chen, George L., additional, Minderman, Hans, additional, Alousi, Amin, additional, Bashey, Asad, additional, Lowsky, Robert, additional, Miklos, David B., additional, Hansen, John, additional, Westervelt, Peter, additional, Yanik, Gregory, additional, Waller, Edmund K., additional, Howard, Alan, additional, Blazar, Bruce R., additional, Wallace, Paul K., additional, Reshef, Ran, additional, Horowitz, Mary M., additional, Maziarz, Richard T., additional, Levine, John E., additional, and Mohammadpour, Hemn, additional

Published
2023
Full Text
View/download PDF

22. 2 adrenergic receptor-mediated signaling regulates the immunosuppressive potential of myeloid-derived suppressor cells

Author

Mohammadpour, Hemn, MacDonald, Cameron R., Qiao, Guanxi, Chen, Minhui, Dong, Bowen, Hylander, Bonnie L., McCarthy, Philip L., Abrams, Scott I., and Repasky, Elizabeth A.

Subjects
Genetically modified organisms -- Health aspects -- Analysis, Catecholamines -- Health aspects -- Analysis, Tumors -- Health aspects -- Analysis, Gene expression -- Health aspects -- Analysis, Stress (Psychology) -- Health aspects -- Analysis, T cells -- Health aspects -- Analysis, Genetic research, Genes, Cancer, Immunotherapy, Health care industry
Abstract

Catecholamines released by sympathetic nerves can activate adrenergic receptors present on nearly every cell type, including myeloid-derived suppressor cells (MDSCs). Using in vitro systems, murine tumor models in wild-type and genetically modified ([beta]2-[AR.sup.-/-]) mice, and adoptive transfer approaches, we found that the degree of [beta]2-AR signaling significantly influences MDSC frequency and survival in tumors and other tissues. It also modulates their expression of immunosuppressive molecules such as arginase-I and PD-L1 and alters their ability to suppress the proliferation of T cells. The regulatory functions of [beta]2-AR signaling in MDSCs were also found to be dependent upon STAT3 phosphorylation. Moreover, we observed that the [beta]2-AR-mediated increase in MDSC survival is dependent upon Fas-FasL interactions, and this is consistent with gene expression analyses, which reveal a greater expression of apoptosis-related genes in [beta]2-[AR.sup.-/-] MDSCs. Our data reveal the potential of [beta]2-AR signaling to increase the generation of MDSCs from both murine and human peripheral blood cells and that the immunosuppressive function of MDSCs can be mitigated by treatment with [beta]-AR antagonists, or enhanced by [beta]-AR agonists. This strongly supports the possibility that reducing stress-induced activation of [beta]2-ARs could help to overcome immune suppression and enhance the efficacy of immunotherapy and other cancer therapies., Introduction A major hallmark of cancer cells is their ability to avoid immune detection and destruction. One mechanism of tumor immune escape is through the accumulation of several immune cell [...]

Published
2019
Full Text
View/download PDF

24. The Sequence of Cyclophosphamide and Myeloablative Total Body Irradiation in Hematopoietic Cell Transplantation for Patients with Acute Leukemia

Author

Holter-Chakrabarty, Jennifer L, Pierson, Namali, Zhang, Mei-Jie, Zhu, Xiaochun, Akpek, Görgün, Aljurf, Mahmoud D, Artz, Andrew S, Baron, Frédéric, Bredeson, Christopher N, Dvorak, Christopher C, Epstein, Robert B, Lazarus, Hillard M, Olsson, Richard F, Selby, George B, Williams, Kirsten M, Cooke, Kenneth R, Pasquini, Marcelo C, and McCarthy, Philip L

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Hematology, Stem Cell Research - Nonembryonic - Human, Clinical Research, Transplantation, Cancer, Childhood Leukemia, Genetics, Pediatric Cancer, Stem Cell Research, Regenerative Medicine, Rare Diseases, Pediatric, Pediatric Research Initiative, Good Health and Well Being, Acute Disease, Adolescent, Adult, Child, Child, Preschool, Cyclophosphamide, Female, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Humans, Immunosuppressive Agents, Infant, Infant, Newborn, Leukemia, Male, Middle Aged, Myeloablative Agonists, Prospective Studies, Recurrence, Risk, Siblings, Survival Analysis, Transplantation Conditioning, Transplantation, Homologous, Unrelated Donors, Whole-Body Irradiation, Allogeneic transplantation, Total body irradiation, Clinical Sciences, Immunology, Cardiovascular medicine and haematology
Abstract

Limited clinical data are available to assess whether the sequencing of cyclophosphamide (Cy) and total body irradiation (TBI) changes outcomes. We evaluated the sequence in 1769 (CyTBI, n = 948; TBICy, n = 821) recipients of related or unrelated hematopoietic cell transplantation who received TBI (1200 to 1500 cGY) for acute leukemia from 2003 to 2010. The 2 cohorts were comparable for median age, performance score, type of leukemia, first complete remission, Philadelphia chromosome-positive acute lymphoblastic leukemia, HLA-matched siblings, stem cell source, antithymocyte globulin use, TBI dose, and type of graft-versus-host disease (GVHD) prophylaxis. The sequence of TBI did not significantly affect transplantation-related mortality (24% versus 23% at 3 years, P = .67; relative risk, 1.01; P = .91), leukemia relapse (27% versus 29% at 3 years, P = .34; relative risk, .89, P = .18), leukemia-free survival (49% versus 48% at 3 years, P = .27; relative risk, .93; P = .29), chronic GVHD (45% versus 47% at 1 year, P = .39; relative risk, .9; P = .11), or overall survival (53% versus 52% at 3 years, P = .62; relative risk, .96; P = .57) for CyTBI and TBICy, respectively. Corresponding cumulative incidences of sinusoidal obstruction syndrome were 4% and 6% at 100 days (P = .08), respectively. This study demonstrates that the sequence of Cy and TBI does not impact transplantation outcomes and complications in patients with acute leukemia undergoing hematopoietic cell transplantation with myeloablative conditioning.

Published
2015

25. Multiple functional variants in the IL1RL1 region are pretransplant markers for risk of GVHD and infection deaths

Author

Karaesmen, Ezgi, Hahn, Theresa, Dile, Alexander James, Rizvi, Abbas A., Wang, Junke, Wang, Tao, Haagenson, Michael D., Preus, Leah, Zhu, Qianqian, Liu, Qian, Yan, Li, Liu, Song, Haiman, Christopher A., Stram, Daniel, Pooler, Loreall, Sheng, Xin, Van Den Berg, David, Brock, Guy, Webb, Amy, McCarthy, Philip L., Pasquini, Marcelo C., Spellman, Stephen R., Lee, Stephanie J., Paczesny, Sophie, and Sucheston-Campbell, Lara E.

Published
2019
Full Text
View/download PDF

26. Robust Quality Infrastructure is Key to Safe and Effective Delivery of Immune Effector Cells: How FACT-Finding Can Help

Author

Curran, Kevin J., primary, Nikiforow, Sarah, additional, Bachier, Carlos, additional, Hsu, Yen-Michael, additional, Maloney, David G, additional, Maus, Marcela V, additional, McCarthy, Philip L., additional, Porter, David L., additional, Shi, Patricia A, additional, Shpall, Elizabeth J, additional, William, Basem, additional, Wacker, Kara, additional, Warkentin, Phyllis, additional, and Heslop, Helen E, additional

Published
2023
Full Text
View/download PDF

27. Exome chip analyses identify genes affecting mortality after HLA-matched unrelated-donor blood and marrow transplantation

Author

Zhu, Qianqian, Yan, Li, Liu, Qian, Zhang, Chi, Wei, Lei, Hu, Qiang, Preus, Leah, Clay-Gilmour, Alyssa I., Onel, Kenan, Stram, Daniel O., Pooler, Loreall, Sheng, Xin, Haiman, Christopher A., Zhu, Xiaochun, Spellman, Stephen R., Pasquini, Marcelo, McCarthy, Philip L., Liu, Song, Hahn, Theresa, and Sucheston-Campbell, Lara E.

Published
2018
Full Text
View/download PDF

29. Anti–Platelet-Derived Growth Factor Receptor Alpha Chain Antibodies Predict for Response to Nilotinib in Steroid-Refractory or -Dependent Chronic Graft-Versus-Host Disease

Author

Chen, George L., Carpenter, Paul A., Broady, Raewyn, Gregory, Tara K., Johnston, Laura J., Storer, Barry E., Beumer, Jan H., Qiu, Jingxin, Cerda, Kiara, Le, Ryan, Otani, Joanne M., Liu, Hong, Ross, Maureen A., Arai, Sally, Flowers, Mary E.D., McCarthy, Philip L., and Miklos, David B.

Published
2018
Full Text
View/download PDF

33. Associations of minor histocompatibility antigens with outcomes following allogeneic hematopoietic cell transplantation

Author

Jadi, Othmane, primary, Tang, Hancong, additional, Olsen, Kelly, additional, Vensko, Steven, additional, Zhu, Qianqian, additional, Wang, Yiwen, additional, Haiman, Christopher A., additional, Pooler, Loreall, additional, Sheng, Xin, additional, Brock, Guy, additional, Webb, Amy, additional, Pasquini, Marcelo C., additional, McCarthy, Philip L., additional, Spellman, Stephen R., additional, Hahn, Theresa, additional, Vincent, Benjamin, additional, Armistead, Paul, additional, and Sucheston‐Campbell, Lara E., additional

Published
2023
Full Text
View/download PDF

34. Abstract 6785: Dendritic cell/myeloma fusion vaccine with lenalidomide maintenance following autologous hematopoietic cell transplant induced T cell activation and expansion

Author

Cheloni, Giulia, primary, Karagkouni, Dimitra, additional, Torres, Daniela, additional, Chung, David J., additional, Shah, Nina, additional, Callander, Natalie S., additional, Chodon, Thinle, additional, Efebera, Yvonne, additional, Geller, Nancy, additional, Hematti, Peiman, additional, Lazarus, Hillard, additional, Malek, Ehsan, additional, McCarthy, Philip L., additional, Nooka, Ajay K., additional, Rosenblatt, Jacalyn, additional, Rapoport, Aaron P., additional, Soiffer, Robert J., additional, Stroopinsky, Dina, additional, Waller, Edmund K., additional, Pasquini, Marcelo C., additional, Vlachos, Ioannis, additional, and Avigan, David, additional

Published
2023
Full Text
View/download PDF

35. Replication and validation of genetic polymorphisms associated with survival after allogeneic blood or marrow transplant

Author

Karaesmen, Ezgi, Rizvi, Abbas A., Preus, Leah M., McCarthy, Philip L., Pasquini, Marcelo C., Onel, Kenan, Zhu, Xiaochun, Spellman, Stephen, Haiman, Christopher A., Stram, Daniel O., Pooler, Loreall, Sheng, Xin, Zhu, Qianqian, Yan, Li, Liu, Qian, Hu, Qiang, Webb, Amy, Brock, Guy, Clay-Gilmour, Alyssa I., Battaglia, Sebastiano, Tritchler, David, Liu, Song, Hahn, Theresa, and Sucheston-Campbell, Lara E.

Published
2017
Full Text
View/download PDF

36. Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial

Author

Holstein, Sarah A, Jung, Sin-Ho, Richardson, Paul G, Hofmeister, Craig C, Hurd, David D, Hassoun, Hani, Giralt, Sergio, Stadtmauer, Edward A, Weisdorf, Daniel J, Vij, Ravi, Moreb, Jan S, Callander, Natalie S, van Besien, Koen, Gentile, Teresa G, Isola, Luis, Maziarz, Richard T, Bashey, Asad, Landau, Heather, Martin, Thomas, Qazilbash, Muzaffar H, Rodriguez, Cesar, McClune, Brian, Schlossman, Robert L, Smith, Scott E, Hars, Vera, Owzar, Kouros, Jiang, Chen, Boyd, Molly, Schultz, Chelsea, Wilson, Marcia, Hari, Parameswaran, Pasquini, Marcelo C, Horowitz, Mary M, Shea, Thomas C, Devine, Steven M, Linker, Charles, Anderson, Kenneth C, and McCarthy, Philip L

Published
2017
Full Text
View/download PDF

38. Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma

Author

Dimopoulos, Meletios A., Jakubowiak, Andrzej J., McCarthy, Philip L., Orlowski, Robert Z., Attal, Michel, Bladé, Joan, Goldschmidt, Hartmut, Weisel, Katja C., Ramasamy, Karthik, Zweegman, Sonja, Spencer, Andrew, Huang, Jeffrey S. Y., Lu, Jin, Sunami, Kazutaka, Iida, Shinsuke, Chng, Wee-Joo, Holstein, Sarah A., Rocci, Alberto, Skacel, Tomas, Labotka, Richard, Palumbo, Antonio, and Anderson, Kenneth C.

Published
2020
Full Text
View/download PDF

43. The Sequence of Cyclophosphamide and Myeloablative Total Body Irradiation in Hematopoietic Cell Transplantation for Patients with Acute Leukemia

Author

Holter-Chakrabarty, Jennifer L., Pierson, Namali, Zhang, Mei-Jie, Zhu, Xiaochun, Akpek, Görgün, Aljurf, Mahmoud D., Artz, Andrew S., Baron, Frédéric, Bredeson, Christopher N., Dvorak, Christopher C., Epstein, Robert B., Lazarus, Hillard M., Olsson, Richard F., Selby, George B., Williams, Kirsten M., Cooke, Kenneth R., Pasquini, Marcelo C., and McCarthy, Philip L.

Published
2015
Full Text
View/download PDF

46. Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research

Author

Arai, Sally, Arora, Mukta, Wang, Tao, Spellman, Stephen R., He, Wensheng, Couriel, Daniel R., Urbano-Ispizua, Alvaro, Cutler, Corey S., Bacigalupo, Andrea A., Battiwalla, Minoo, Flowers, Mary E., Juckett, Mark B., Lee, Stephanie J., Loren, Alison W., Klumpp, Thomas R., Prockup, Susan E., Ringdén, Olle T.H., Savani, Bipin N., Socié, Gérard, Schultz, Kirk R., Spitzer, Thomas, Teshima, Takanori, Bredeson, Christopher N., Jacobsohn, David A., Hayashi, Robert J., Drobyski, William R., Frangoul, Haydar A., Akpek, Görgün, Ho, Vincent T., Lewis, Victor A., Gale, Robert Peter, Koreth, John, Chao, Nelson J., Aljurf, Mahmoud D., Cooper, Brenda W., Laughlin, Mary J., Hsu, Jack W., Hematti, Peiman, Verdonck, Leo F., Solh, Melhelm M., Norkin, Maxim, Reddy, Vijay, Martino, Rodrigo, Gadalla, Shahinaz, Goldberg, Jenna D., McCarthy, Philip L., Pérez-Simón, José A., Khera, Nandita, Lewis, Ian D., Atsuta, Yoshiko, Olsson, Richard F., Saber, Wael, Waller, Edmund K., Blaise, Didier, Pidala, Joseph A., Martin, Paul J., Satwani, Prakash, Bornhäuser, Martin, Inamoto, Yoshihiro, Weisdorf, Daniel J., Horowitz, Mary M., and Pavletic, Steven Z.

Published
2015
Full Text
View/download PDF

47. Shared graft-vs-leukemia minor histocompatibility antigens in DISCOVeRY-BMT

Author

Olsen, Kelly Shea, primary, Jadi, Othmane, additional, Dexheimer, Sarah, additional, Bortone, Dante S, additional, Vensko, Steven P, additional, Bennett, Sarah Nicole, additional, Tang, Hancong, additional, Diiorio, Marisa, additional, Saran, Tanvi, additional, Dingfelder, David, additional, Zhu, Qianqian, additional, Wang, Yiwen, additional, Haiman, Christopher A, additional, Pooler, Loreall, additional, Sheng, Xin, additional, Webb, Amy, additional, Pasquini, Marcelo C., additional, McCarthy, Philip L., additional, Spellman, Stephen R., additional, Weimer, Eric T., additional, Hahn, Theresa, additional, Sucheston-Campbell, Lara E, additional, Armistead, Paul M, additional, and Vincent, Benjamin, additional

Published
2022
Full Text
View/download PDF

48. ZUMA-19: A Phase 1/2 Study of Axicabtagene Ciloleucel Plus Lenzilumab in Patients With Relapsed or Refractory Large B-Cell Lymphoma

Author

Oluwole, Olalekan O., primary, Kenderian, Saad S., additional, Shiraz, Parveen, additional, Karmali, Reem, additional, Reshef, Ran, additional, McCarthy, Philip L., additional, Ghosh, Nilanjan, additional, Lazaryan, Aleksandr, additional, Filosto, Simone, additional, Poddar, Soumya, additional, Mao, Daqin, additional, Peng, Andrew, additional, Kilcoyne, Adrian, additional, Nahas, Myrna, additional, and Neelapu, Sattva S., additional

Published
2022
Full Text
View/download PDF

49. Multivariable Analyses of Prognostic Factors for Progression-Free Survival (PFS) and Complete Response (CR) with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial

Author

Hassoun, Hani, primary, Jacobus, Susanna J., additional, Richardson, Paul G., additional, Zonder, Jeffrey A., additional, Voorhees, Peter M., additional, Kaufman, Jonathan L., additional, Yee, Andrew J., additional, Scott, Emma C., additional, Torka, Pallawi, additional, Libby, Edward, additional, Reeves, Brandi, additional, Wang, Michael L., additional, Anderson, Larry D., additional, Milner, Carter, additional, Gasparetto, Cristina J., additional, Agha, Mounzer, additional, Khan, Abdullah, additional, Hurd, David Duane, additional, Avigan, David, additional, Costello, Caitlin, additional, Jakubowiak, Andrzej, additional, Lonial, Sagar, additional, Raje, Noopur, additional, Medvedova, Eva, additional, McCarthy, Philip L., additional, Orlowski, Robert Z., additional, Nadeem, Omar, additional, Laubach, Jacob P., additional, Pasquini, Marcelo C., additional, Giralt, Sergio A., additional, Masone, Kelly, additional, Samur, Mehmet K., additional, Perrot, Aurore, additional, Moreau, Philippe, additional, Avet-Loiseau, Herve, additional, Weller, Edie A., additional, Munshi, Nikhil C., additional, and Anderson, Kenneth C., additional

Published
2022
Full Text
View/download PDF

50. Associations of Minor Histocompatibility Antigens with Clinical Outcomes Following Allogeneic Hematopoietic Cell Transplantation

Author

Jadi, Othmane, primary, Tang, Hancong, additional, Olsen, Kelly Shea, additional, Vensko, Steven, additional, Zhu, Qianqian, additional, Wang, Yiwen, additional, Haiman, Christopher A., additional, Pooler, Loreall, additional, Sheng, Xin, additional, Brock, Guy, additional, Webb, Amy, additional, Pasquini, Marcelo C, additional, McCarthy, Philip L., additional, Spellman, Stephen R., additional, Hahn, Theresa E., additional, Vincent, Benjamin G., additional, Armistead, Paul M., additional, and Sucheston-Campbell, Lara E., additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results